Keywords
How to Cite
Abstract
Neoadjuvant systemic therapy is frequently used option for the systemic treatment for breast cancer. Inclusion in the regimen of targeted drugs as trastuzumab (Herceptin®) and pertuzumab significantly improves outcomes in HER2-positive breast cancer patients. A certain part of HER2-positive patients can be cured by using only targeted drugs without chemotherapy.References
Семиглазов В.Ф., Манихас А.Г, Семиглазова Т.Ю., Бессонов А.А., Семиглазов В.В. Неоадъювантная системная терапия рака молочной железы (руководство). Аграф. — 2012. — 112 с.
Abramson V., Arteaga C. New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available // Clin Cancer Res. — 2011. — Vol. 17. — P. 952-958.
Agus D., Akita R., Fox W. et al.Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth // Cancer Cell. — 2002. — Vol. 2. — P 127-137.
Baselga J., Carbonell X., Castanada-Soto N. Phase II study of efficacy, safety and pharmacokinetics of trastuzumabmonotherapy administered on a 3-weekly schedule // J Clin Oncol. — 2005. — Vol. 23. — P 21622171.
Baselga J., Gelmon K., Verma S. et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy // J Clin Oncol. — 2010. — Vol. 28. — P 11381144.
Baselga J., Semiglazov V., van Dam P et.al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor — positive breast cancer // J.Clin Oncol. — 2009. -Vol.-27(6). — P 2630-2637.
Bianchi G., Albanell J., Eiermann W. et al. Cancer Regimen for Women with HER2-Positive Advanced Breast Doxorubicin Component of a Doxorubicin plus Paclitaxel // Clin Cancer Res. — 2003. — Vol. 9. — P 5944-5951.
Buzdar A., Ibrahim N., Francis D., Booser D., Thomas E., Theriault R. Significantly higher pathological complete remission (PCR) rate after neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin chemotherapy; results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer // J Clin Oncol. — 2005. — Vol. 23. — P 3676-3685.
Franklin M., Carey K., Vajdos F., Leahy D., de Vos A., Sliwkowski M. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex // Cancer Cell. — 2004. — Vol. 61. — P 4744-4749.
Gianni L, Eiermann W, Semiglazov V et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2 — positive locally advanced breast cancer (the NOAH trial): a randomized controlled superiority trial with a parallel HER2 — negative cohort // Lancet. — 2010. — Vol. 375. — P 377-384.
Gianni L., Baselga J., Eiermann W., Porta J., Semiglazov V. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate and fluorouracili as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer // J Clin Oncol. — 2009. — Vol. 27. — № 15. — P. 2474-2481.
Gluck S., McKenna E., Royce M. Capecitabine plus docetaxel, with or without trastuzumab, as preoperative therapy for early breast cancer // Int Med Sci. — 2008. — Vol.5. — P341-346.
Junttila T., Sundvall M., Elenius K. Erbb4 and its isoforms: selective regulation of growth factor responses by naturally occurring receptor variants // Trends Cardiovasc Med. — 2000. — Vol. 10(7). — P. 304-310.
Marty M., Cognetti F., Maraninchi D. et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group // J Clin Oncol. — 2005. — Vol. 23. — P. 4265-4274.
Molina M., Codony-Servat J., Albanell J., Rojo F., Arribas J., Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells // Cancer Res. — 2001. — Vol. 61 (12). — P. 47444749.
Piccart-Gebhart M., Procter M., Leyland-Jones B. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer // N Engl J Med. — 2005. — Vol. 353. — P. 1659-1672.
Romond E., Perez E., Bryant J. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer // N Engl J Med. — 2005. — Vol. 353. — P 16731684.
Ross J., Slodkowska E., Symmans W. et al. The HER-2 receptor and breast cancer: ten years of targeted anti — HER-2 therapy and personalized medicine // Oncologist. — 2009. — Vol. 14. — P. 320-368.
Scheuer W., Friess T., Burtscher H., Bossenmaier B., Endl J., Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models // Cancer Res. — 2009. — Vol. 69. — P 9330-9336.
Slamon D., Eiermann W. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (FC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2-positive early breast cancer patients: BCIRG 006 study // Breast Cancer Res Treat. — 2005. — Vol. 94 (suppl.1). — P. 5.
Slamon D., Leyland-Jones B., Shak S. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2 // N Engl J Med. — 2001. — Vol. 344. — P 783-792.
Smith I., Procter M., Gelber R. et al. For the HERA study team 2 year Follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial // Lancet. — 2007. — Vol. 369. — P. 29-36.
Untch M., Rezai M., Loibl S. Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin / cyclophosphamidr followed by docetaxel / capecitabine: first analysis of efficacy and safety of the GBG // AGO multicenter intergroup-study “GeparQuattro” (abstr. 1LB) // European Breast Cancer Conference. — 2008. — April, 15-19. — Berlin, Germany.
Von Minckiwitz G., Rezai M., Loibl S. et al. Effect of trastuzumab on pathologic complete response rate of neoadjuvant EC-docetaxel treatment in HER2-overexpressur breast cancer: Results of the phase III Gepar-Qattro study (abstract 226) //ASCO Breast Cancer Symposium. — 2008.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...